LIANHE TECHNOLOGY(SZ:002250)2023-07-25 09:11Group 1: Company Performance - The company's performance in the first half of the year has declined compared to the same period last year, primarily due to clients entering a "de-inventory" phase, leading to a decrease in revenue from the plant protection division and a subsequent drop in net profit [1] - The company aims to enhance production, research and management capabilities to improve research strength, optimize capacity, and expand the market for rapid development [1] Group 2: Pharmaceutical Business Development - The pharmaceutical business has shown steady growth compared to last year, with verification projects progressing as planned, and some projects already completed and gradually ramping up production [1] - The company is actively seeking to expand new verification projects, which, if successfully completed and commercialized, could significantly contribute to future growth in the pharmaceutical sector [1] Group 3: New Energy Products - The lithium hexafluorophosphate product is currently in the trial production phase, with ongoing efforts to ensure quality and stability in production and capacity ramp-up [2] - The development of lithium bis(fluorosulfonyl)imide is also proceeding according to plan [2] Group 4: Investment and Strategic Decisions - The company has decided to increase capital investment in Helio to strengthen its functional chemicals segment and enhance the management team's effectiveness, aiming to share operational results with shareholders and employees [2] - To address challenges after the expiration of patents on key products, the company plans to optimize processes to reduce production costs and actively secure new orders to ensure stable business development [2]